Advances in research and development of echinococcosis vaccines_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

GU Hanfei , MOU Jun ,  LIU Jie

Center for Infectious Disease and Vaccine Research, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;

Corresponding?author：

LIU Jie, Email: drliu@scu.edu.cn

Keywords：

Echinococcus; echinococcosis; vaccine; prevention; control

DOI：

10.7507/1007-9424.202408103

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Echinococcosis is a zoonotic and parasitic disease caused by tapeworms of the genus Echinococcus. The most common forms of the disease are cystic echinococcosis (CE) and alveolar echinococcosis (AE), caused by Echinococcus granulosus and Echinococcus mutilocularis, respectively, and posing a serious health challenge and economic burden to human society. The most adapted treatment is surgical excision plus chemotherapy, although which mostly is effective, the traumatic damage from the invasive procedure and the adverse effects of the prolonged chemotherapy are profound. Conventional preventions include controlling the source of infection, improving the sanitation in livestock slaughter, strengthening surveillance, and increasing public health education. However, the outcome is limited by the complicity of the geographical nature, cultural background, and unique lifestyle. Vaccination is the most safe and cost-effective way to control infectious diseases. The partial success of recombinant Eg95 as a veterinary vaccine had established a theoretical foundation for the development of a human echinococcosis vaccine, which will shed a light on the prevention, control, and eventual elimination of the human infection. There are promising vaccine candidates in the research and development pipelines in the form of parasite tissue extract proteins, recombinant proteins, nucleic acids, synthetic antigenic epitopes, and vector vaccines. These candidates have shown potential to induce protective humoral and cellular immune responses that block the invasion, eradicate the worm at an early stage, or prevent the onset of infection. We reviewed the progress in the vaccine development and discussed the challenges and solutions in the research and development to facilitate the licensure of a vaccine against human echinococcosis.

Citation： GU Hanfei, MOU Jun, LIU Jie. Advances in research and development of echinococcosis vaccines. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2024, 31(10): 1170-1180. doi: 10.7507/1007-9424.202408103 Copy

1.	McManus DP, Zhang W, Li J, et al. Echinococcosis. Lancet, 2003, 362(9392): 1295-1304.
2.	溫浩, 徐明謙. 實用包蟲病學. 北京: 科學出版社, 2007.
3.	Eckert J, Deplazes P. Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. Clin Microbiol Rev, 2004, 17(1): 107-135.
4.	Mandal S, Mandal MD. Human cystic echinococcosis: epidemiologic, zoonotic, clinical, diagnostic and therapeutic aspects. Asian Pac J Trop Med, 2012, 5(4): 253-260.
5.	中國醫師協會外科醫師分會包蟲病外科專業委員會. 肝兩型包蟲病診斷與治療專家共識(2019版). 中華消化外科雜志, 2019, 18(8): 711-721.
6.	唐桂波, 張強, 郭亞民, 等. 臨床包蟲病學. 北京: 人民衛生出版社, 2022.
7.	WHO. Echinococcosis. 2021. https://www.who.int/en/news-room/fact-sheets/detail/echinococcosis.
8.	World Health Organization?. Fact sheet on echinococcosis (?updated May 2019)?. Weekly Epidemiological Record, 2019, 94(?48): ?574-579.
9.	伍衛平, 王虎, 王謙, 等. 2012–2016年中國棘球蚴病抽樣調查分析. 中國寄生蟲學與寄生蟲病雜志, 2018, 36(1): 1-14.
10.	喻文杰, 王謙, 廖沙, 等. 2017年四川省石渠縣包蟲病患病情況現狀調查. 預防醫學情報雜志, 2018, 34(5): 545-549.
11.	王健, 王文濤. 肝包蟲病診療進展. 中華肝臟外科手術學電子雜志, 2022, 11(4): 351-355.
12.	Joliat GR, Labgaa I, Demartines N, et al. Preoperative albumin level is a marker of alveolar echinococcosis recurrence after hepatectomy. World J Gastroenterol, 2017, 23(5): 853-858.
13.	Wen H, Vuitton L, Tuxun T, et al. Echinococcosis: advances in the 21st century. Clin Microbiol Rev, 2019, 32(2): e00075-18. doi: 10.1128/CMR.00075-18.
14.	王志鑫, 劉云飛, 王灝, 等. 肝泡型包蟲病的診治進展. 器官移植, 2024, 15(2): 171-177.
15.	楊柳瑩, 陳曦陽, 凌攀, 等. 包蟲病特異性抗體檢測試劑盒診斷效能評價及結果判定優化. 寄生蟲與醫學昆蟲學報, 2021, 28(3): 143-147.
16.	劉文亞, 蔣奕, 王健. 肝包蟲病影像學診斷專家共識. 臨床肝膽病雜志, 2021, 37(4): 792-797.
17.	Brunetti E, Kern P, Vuitton DA, et al. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop, 2010, 114(1): 1-16.
18.	WHO. Working to overcome the global impact of neglected tropical diseases: first WHO report on neglected tropical diseases: summary. Geneva: World Health Organization, 2010.
19.	WHO. Global report on neglected tropical diseases 2024. Geneva: World Health Organization, 2024.
20.	Rong X, Fan M, Zhu H, et al. Dynamic modeling and optimal control of cystic echinococcosis. Infect Dis Poverty, 2021, 10(1): 38. doi: 10.1186/s40249-021-00807-6.
21.	Nabarro LE, Amin Z, Chiodini PL. Current management of cystic echinococcosis: a survey of specialist practice. Clin Infect Dis, 2015, 60(5): 721-728.
22.	Gu H, Hu Y, Guo S, et al. China’s prevention and control experience of echinococcosis: A 19-year retrospective. J Helminthol, 2024, 98: e16. doi: 10.1017/S0022149X24000014.
23.	健康中國2030規劃綱要. 中華眼科雜志, 2018, 54(1): 11-22.
24.	Nandi A, Shet A. Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination. Hum Vaccin Immunother, 2020, 16(8): 1900-1904.
25.	Lightowlers MW, Lawrence SB, Gauci CG, et al. Vaccination against hydatidosis using a defined recombinant antigen. Parasite Immunol, 1996, 18(9): 457-462.
26.	Larrieu E, Gavidia CM, Lightowlers MW. Control of cystic echinococcosis: Background and prospects. Zoonoses Public Health, 2019, 66(8): 889-899.
27.	Reuben JM, Tanner CE, Rau ME. Immunoprophylaxis with BCG of experimental Echinococcus multilocularis infections. Infect Immun, 1978, 21(1): 135-139.
28.	Ritz N, Hanekom WA, Robins-Browne R, et al. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev, 2008, 32(5): 821-841.
29.	Lange C, Aaby P, Behr MA, et al. 100 years of Mycobacterium bovis bacille Calmette-Guérin. Lancet Infect Dis, 2022, 22(1): e2-e12. doi: 10.1016/S1473-3099(21)00403-5.
30.	Hataminejad M, Anvari D, Khaleghi N, et al. Current status and future prospects of Echinococcus multilocularis vaccine candidates: A systematic review. Vet Anim Sci, 2024, 24: 100345. doi: 10.1016/j.vas.2024.100345.
31.	Rrudneva VG, Berezhko K, Sasikova R. Immunoprophylaxis of secondary alveolar echinococcosis by a immunostimulation ribotan combined with antigen protoscolex cells of Echinococcus multilocularis. Interdisciplinary Scientific Conference for PhD students and assistants, 2016.
32.	Kouguchi H, Matsumoto J, Nakao R, et al. Characterization of a surface glycoprotein from Echinococcus multilocularis and its mucosal vaccine potential in dogs. PLoS One, 2013, 8(7): e69821. doi: 10.1371/journal.pone.0069821.
33.	Hashemitabar GR, Razmi GR, Naghibi A. Trials to induce protective immunity in mice and sheep by application of protoscolex and hydatid fluid antigen or whole body antigen of Echinococcus granulosus. J Vet Med B Infect Dis Vet Public Health, 2005, 52(5): 243-245.
34.	Hassan H, Al Hadithi TS, Al Sakee HM. Experimental trial with a heat-shocked protoscolex extract as a vaccine candidate for protection against hydatid disease. Turkiye Parazitol Derg, 2016, 40(1): 1-8.
35.	Zhang W, Zhang Z, Shi B, et al. Vaccination of dogs against Echinococcus granulosus, the cause of cystic hydatid disease in humans. J Infect Dis, 2006, 194(7): 966-974.
36.	Kandil OM, Abdelrahman KA, Mahmoud MS, et al. Cystic echinococcosis: Development of an intermediate host rabbit model for using in vaccination studies. Exp Parasitol, 2020, 208: 107800. doi: 10.1016/j.exppara.2019.107800.
37.	El-Aal AA, El-Gebaly NS, Al-Antably AS, et al. Post-immunization immunohistochemical expression of Caspase 3 and p53 apoptotic markers in experimental hydatidosis. Rev Bras Parasitol Vet, 2016, 25(3): 333-340.
38.	Poggio TV, Jensen O, Mossello M, et al. Serology and longevity of immunity against Echinococcus granulosus in sheep and llama induced by an oil-based EG95 vaccine. Parasite Immunol, 2016, 38(8): 496-502.
39.	Gottstein B, Wunderlin E, Tanner I. Echinococcus multilocularis: parasite-specific humoral and cellular immune response subsets in mouse strains susceptible (AKR, C57B1/6J) or ‘resistant’ (C57B1/10) to secondary alveolar echinococcosis. Clin Exp Immunol, 1994, 96(2): 245-252.
40.	Jazouli M, Lightowlers MW, Bamouh Z, et al. Immunological responses and potency of the EG95NC^– recombinant sheep vaccine against cystic echinococcosis. Parasitol Int, 2020, 78: 102149. doi: 10.1016/j.parint.2020.102149.
41.	Barnes TS, Hinds LA, Jenkins DJ, et al. Efficacy of the EG95 hydatid vaccine in a macropodid host, the tammar wallaby. Parasitology, 2009, 136(4): 461-468.
42.	Heath DD, Robinson C, Lightowlers MW. Maternal antibody parameters of cattle and calves receiving EG95 vaccine to protect against Echinococcus granulosus. Vaccine, 2012, 30(50): 7321-7326.
43.	Larrieu E, Herrero E, Mujica G, et al. Pilot field trial of the EG95 vaccine against ovine cystic echinococcosis in Rio Negro, Argentina: early impact and preliminary data. Acta Trop, 2013, 127(2): 143-151.
44.	Amarir F, Rhalem A, Sadak A, et al. Control of cystic echinococcosis in the Middle Atlas, Morocco: Field evaluation of the EG95 vaccine in sheep and cesticide treatment in dogs. PLoS Negl Trop Dis, 2021, 15(3): e0009253. doi: 10.1371/journal.pntd.0009253.
45.	Gauci CG, Jenkins DJ, Lightowlers MW. Protection against cystic echinococcosis in sheep using an Escherichia coli-expressed recombinant antigen (EG95) as a bacterin. Parasitology, 2022, 150(1): 1-3.
46.	Lightowlers MW, Jensen O, Fernandez E, et al. Vaccination trials in Australia and Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep. Int J Parasitol, 1999, 29(4): 531-534.
47.	Gauci C, Lightowlers MW. Molecular cloning of genes encoding oncosphere proteins reveals conservation of modular protein structure in cestode antigens. Mol Biochem Parasitol, 2003, 127(2): 193-198.
48.	張壯志, 石保新, 張文寶, 等. 綿羊包蟲病基因工程疫苗(Eg95)免疫試驗. 中國人獸共患病學報, 2008, 24(3): 252-256.
49.	Woollard DJ, Gauci CG, Heath DD, et al. Protection against hydatid disease induced with the EG95 vaccine is associated with conformational epitopes. Vaccine, 2000, 19(4-5): 498-507.
50.	張藝琳. EG95誘導的抗體應答在細粒棘球蚴感染中的保護機制. 成都: 四川大學, 2021.
51.	Jazouli M, Lightowlers M, Gauci CG, et al. Vaccination against hydatidosis: Molecular cloning and optimal expression of the EG95NC^– recombinant antigen in Escherichia coli. Protein J, 2017, 36(6): 472-477.
52.	Pourseif MM, Moghaddam G, Nematollahi A, et al. Vaccination with rEGVac elicits immunoprotection against different stages of Echinococcus granulosus life cycle: A pilot study. Acta Trop, 2021, 218: 105883. doi: 10.1016/j.actatropica.2021.105883.
53.	Zhang ZZ, Guo G, Li J, et al. Dog vaccination with EgM proteins against Echinococcus granulosus. Infect Dis Poverty, 2018, 7(1): 61. doi: 10.1186/s40249-018-0425-4.
54.	Shi Z, Wang Y, Li Z, et al. Cloning, expression, and protective immunity in mice of a gene encoding the diagnostic antigen P-29 of Echinococcus granulosus. Acta Biochim Biophys Sin (Shanghai), 2009, 41(1): 79-85.
55.	Li ZJ, Wang YN, Wang Q, et al. Echinococcus granulosus 14-3-3 protein: a potential vaccine candidate against challenge with Echinococcus granulosus in mice. Biomed Environ Sci, 2012, 25(3): 352-358.
56.	Li Z, Ding S, Li Y. Study on the immunity protection of 14-3-3-MPLA-liposome vaccine against cystic echinococcosis in mice. Front Lab Med, 2018, 2(4): 146-151.
57.	Arbildi P, Muniz-Lagos AC, Fernández E, et al. Immunization with a Mu-class glutathione transferase from Echinococcus granulosus induces efficient antibody responses and confers long-term protection against secondary cystic echinococcosis. Microbes Infect, 2024, 26(5-6): 105364. doi: 10.1016/j.micinf.2024.105364.
58.	Siles-Lucas M, Merli M, Mackenstedt U, et al. The Echinococcus multilocularis 14-3-3 protein protects mice against primary but not secondary alveolar echinococcosis. Vaccine, 2003, 21(5-6): 431-439.
59.	Dang Z, Yagi K, Oku Y, et al. Evaluation of Echinococcus multilocularis tetraspanins as vaccine candidates against primary alveolar echinococcosis. Vaccine, 2009, 27(52): 7339-7345.
60.	Kouguchi H, Matsumoto J, Katoh Y, et al. The vaccination potential of EMY162 antigen against Echinococcus multilocularis infection. Biochem Biophys Res Commun, 2007, 363(4): 915-920.
61.	Gauci C, Merli M, Muller V, et al. Molecular cloning of a vaccine antigen against infection with the larval stage of Echinococcus multilocularis. Infect Immun, 2002, 70(7): 3969-3972.
62.	Chen L, Cheng Z, Xian S, et al. Immunization with Em CRT-induced protective immunity against Echinococcus multilocularis infection in BALB/c mice. Trop Med Infect Dis, 2022, 7(10): 279. doi: 10.3390/tropicalmed7100279.
63.	Wang H, Li Z, Gao F, et al. Immunoprotection of recombinant Eg. P29 against Echinococcus granulosus in sheep. Vet Res Commun, 2016, 40(2): 73-79.
64.	Müller-Schollenberger V, Beyer W, Schnitzler P, et al. Immunisation with Salmonella typhimurium-delivered glyceraldehyde-3-phosphate dehydrogenase protects mice against challenge infection with Echinococcus multilocularis eggs. Int J Parasitol, 2001, 31(13): 1441-1449.
65.	Wang Y, Li Z, Li Z, et al. Recombinant ferritin protects mice against challenge with Echinococcus granulosus ?. Acta Parasitologica, 2009, 54(4): 335-340.
66.	Sun J, Wang Y, Li Z, et al. Echinococcus granulosus: immunoprotection accompanyied by humoral and cytokine response against secondary hydatidosis in mice immunized with rEg. myophilin. Vet Res Commun, 2011, 35(4): 193-200.
67.	Zhu M, Gao F, Li Z, et al. Immunoprotection of recombinant Eg. myophilin against Echinococcus granulosus infection in sheep. Exp Ther Med, 2016, 12(3): 1585-1590.
68.	Li R, Yang Q, Guo L, et al. Immunological features and efficacy of the recombinant subunit vaccine LTB-EMY162 against Echinococcus multilocularis metacestode. Appl Microbiol Biotechnol, 2018, 102(5): 2143-2154.
69.	Zhu M, Wang X, Wang H, et al. Mechanism of protective immunity by vaccination with recombinant Echinococcus granulosus glutathione S-transferase (Chinese strain) in mice. Exp Ther Med, 2015, 10(3): 1127-1132.
70.	Wang L, Wei W, Zhou P, et al. Enzymatic characteristics and preventive effect of leucine aminopeptidase against Echinococcus multilocularis. Acta Trop, 2021, 222: 106066. doi: 10.1016/j.actatropica.2021.106066.
71.	Boubaker G, Hemphill A, Huber CO, et al. Prevention and immunotherapy of secondary murine alveolar echinococcosis employing recombinant EmP29 antigen. PLoS Negl Trop Dis, 2015, 9(6): e0003795. doi: 10.1371/journal.pntd.0003795.
72.	Li M, Zhu Y, Li Z, et al. Immunoprotective effect and mechanism of rEg. P29 against CD4⁺ T cell-deficient mice with Echinococcus multilocularis infection. Acta Biochim Biophys Sin (Shanghai), 2024, 56(3): 482-489.
73.	Dang Z, Yagi K, Oku Y, et al. A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology. PLoS Negl Trop Dis, 2012, 6(3): e1570. doi: 10.1371/journal.pntd.0001570.
74.	Xian J, Wang N, Zhao P, et al. Molecular characterization and immune protection of the 3-hydroxyacyl-CoA dehydrogenase gene in Echinococcus granulosus. Parasit Vectors, 2021, 14(1): 489. doi: 10.1186/s13071-021-05001-z.
75.	Shao G, Hua R, Song H, et al. Protective efficacy of six recombinant proteins as vaccine candidates against Echinococcus granulosus in dogs. PLoS Negl Trop Dis, 2023, 17(10): e0011709. doi: 10.1371/journal.pntd.0011709.
76.	Xian J, Zhao P, Wang N, et al. Molecular characterization of a tetraspanin TSP11 gene in Echinococcus granulosus and evaluation its immunoprotection in model dogs. Front Vet Sci, 2021, 8: 759283. doi: 10.3389/fvets.2021.759283.
77.	Virginio VG, Monteiro KM, Drumond F, et al. Excretory/secretory products from in vitro-cultured Echinococcus granulosus protoscoleces. Mol Biochem Parasitol, 2012, 183(1): 15-22.
78.	Esteves A, Portillo V, Ehrlich R. Genomic structure and expression of a gene coding for a new fatty acid binding protein from Echinococcus granulosus. Biochim Biophys Acta, 2003, 1631(1): 26-34.
79.	Fraize M, Sarciron ME, Azzouz S, et al. Immunogenicity of two Echinococcus granulosus antigens EgA31 and EgTrp in mice. Parasitol Res, 2005, 96(2): 113-120.
80.	吳茂迪. 細粒棘球絳蟲PGK、E2D2基因的特征分析及EgFABP-EgA31、EgTPx-EgTrp蛋白免疫保護效果評價. 成都: 四川農業大學, 2019.
81.	葉艷菊. 細粒棘球絳蟲轉Eg95-EgA31融合基因苜蓿疫苗保護力及其免疫機制研究. 重慶: 重慶醫科大學, 2010.
82.	Williams JA, Carnes AE, Hodgson CP. Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production. Biotechnol Adv, 2009, 27(4): 353-370.
83.	Zhao Y, Bi Q, Wei Y, et al. A DNA vaccine (EG95-PT1/2/3-IL2) encoding multi-epitope antigen and IL-2 provokes efficient and long-term immunity to echinococcosis. J Control Release, 2023, 361: 402-416.
84.	Boutennoune H, Qaqish A, Al-Aghbar M, et al. Induction of T helper 1 response by immunization of BALB/c mice with the gene encoding the second subunit of Echinococcus granulosus antigen B (EgAgB8/2). Parasite, 2012, 19(2): 183-188.
85.	Gharibi Z, Rahdar M, Pirestani M, et al. The immunization of protoscolices P29 DNA vaccine on experimental cystic echinococosis in Balb/c mice. Acta Parasitol, 2021, 66(4): 1114-1121.
86.	Azizi H, Kazemi B, BandehpouR M, et al. Modulation of the immune response to DNA vaccine encoding gene of 8-kDa subunit of Echinococcus granulosus antigen B using murine interleukin-12 plasmid in BALB/c mice. Iran J Parasitol, 2016, 11(4): 480-489.
87.	Anvari D, Rezaei F, Ashouri A, et al. Current situation and future prospects of Echinococcus granulosus vaccine candidates: A systematic review. Transbound Emerg Dis, 2021, 68(3): 1080-1096.
88.	Pourseif MM, Moghaddam G, Saeedi N, et al. Current status and future prospective of vaccine development against Echinococcus granulosus. Biologicals, 2018, 51: 1-11.
89.	Pagliari S, Dema B, Sanchez-Martinez A, et al. DNA vaccines: History, molecular mechanisms and future perspectives. J Mol Biol, 2023, 435(23): 168297. doi: 10.1016/j.jmb.2023.168297.
90.	楊先偉, 陶浪, 魏金文, 等. 包蟲病特異性疫苗抗原研究現狀及展望. 中國普外基礎與臨床雜志, 2023, 30(6): 734-738.
91.	Esmaelizad M, Ahmadian G, Aghaiypour K, et al. Induction of prominent Th1 response in C57Bl/6 mice immunized with an E. coli-expressed multi T-cell epitope EgA31 antigen against Echinococcus granulosus. Folia Parasitol (Praha), 2013, 60(1): 28-34.
92.	Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov, 2018, 17(4): 261-279.
93.	Gote V, Bolla PK, Kommineni N, et al. A comprehensive review of mRNA vaccines. Int J Mol Sci, 2023, 24(3): 2700. doi: 10.3390/ijms24032700.
94.	Schlake T, Thess A, Fotin-Mleczek M, et al. Developing mRNA-vaccine technologies. RNA Biol, 2012, 9(11): 1319-1330.
95.	Xu S, Yang K, Li R, et al. mRNA vaccine Era-mechanisms, drug platform and clinical prospection. Int J Mol Sci, 2020, 21(18): 6582. doi: 10.3390/ijms21186582.
96.	Yu M, Zhu Y, Li Y, et al. Design of a novel multi-epitope vaccine against Echinococcus granulosus in immunoinformatics. Front Immunol, 2021, 12: 668492. doi: 10.3389/fimmu.2021.668492.
97.	Lv Y, Zhu Y, Chang L, et al. Identification of a dominant murine T-cell epitope in recombinant protein P29 from Echinococcus granulosus. Acta Biochim Biophys Sin (Shanghai), 2022, 54(4): 482-493.
98.	Zhao X, Zhang F, Li Z, et al. Bioinformatics analysis of EgA31 and EgG1Y162 proteins for designing a multi-epitope vaccine against Echinococcus granulosus. Infect Genet Evol, 2019, 73: 98-108.
99.	Li Y, Zhu Y, Sha T, et al. A multi-epitope chitosan nanoparticles vaccine of canine against Echinococcus granulosus. J Biomed Nanotechnol, 2021, 17(5): 910-920.
100.	An X, Xiang W, Liu X, et al. A bioengineered nanovesicle vaccine boosts T-B cell interaction for immunotherapy of Echinococcus multilocularis. Angew Chem Int Ed Engl, 2024, 63(13): e202319489. doi: 10.1002/anie.202319489.
101.	Petavy AF, Hormaeche C, Lahmar S, et al. An oral recombinant vaccine in dogs against Echinococcus granulosus, the causative agent of human hydatid disease: a pilot study. PLoS Negl Trop Dis, 2008, 2(1): e125. doi: 10.1371/journal.pntd.0000125.
102.	Chabalgoity JA, Moreno M, Carol H, et al. Salmonella typhimurium as a basis for a live oral Echinococcus granulosus vaccine. Vaccine, 2000, 19(4-5): 460-469.
103.	李文桂, 王鴻, 朱佑明. 細粒棘球絳蟲重組BCG-Eg95疫苗誘導小鼠脾細胞淋巴因子變化的研究. 中國寄生蟲學與寄生蟲病雜志, 2007, 25(2): 109-113.
104.	Ebrahimzadeh F, Shirdast H, Taromchi A, et al. Induction of immunogenic response in BALB/c mice by live and killed form of recombinant lactococcus lactis displaying EG95 of Echinococcus granulosus. Iran Biomed J, 2021, 25(4): 284-296.
105.	周必英, 李文桂. 細粒棘球絳蟲重組Bb-Eg95疫苗誘導小鼠體液免疫應答的動態觀察. 中國病原生物學雜志, 2012, 7(7): 513-515.
106.	Xu T, Liu L, Shi C, et al. A recombinant rabies virus expressing Echinococcus granulosus EG95 induces protective immunity in mice. Transbound Emerg Dis, 2022, 69(4): e254-e266. doi: 10.1111/tbed.14292.
107.	Ma X, Zhao H, Zhang F, et al. Activity in mice of recombinant BCG-EgG1Y162 vaccine for Echinococcus granulosus infection. Hum Vaccin Immunother, 2016, 12(1): 170-175.
108.	周必英, 陳雅棠, 李文桂, 等. 細粒棘球絳蟲重組Bb-Eg95-EgA31疫苗誘導小鼠脾細胞因子變化的研究. 中國寄生蟲學與寄生蟲病雜志, 2010, 28(4): 268-272.
109.	李文桂, 王鴻, 朱佑明. 多房棘球絳蟲混合重組BCG-EmⅡ/3和BCG-Em14-3-3疫苗誘導小鼠的免疫保護力觀察. 第三軍醫大學學報, 2007, 29(13): 1276-1279.
110.	楊梅, 李文桂. 多房棘球絳蟲重組Bb-EmⅡ/3-Em14-3-3疫苗誘導小鼠細胞因子變化的研究. 細胞與分子免疫學雜志, 2008, 24(8): 781-784.
111.	Gottstein B, Soboslay P, Ortona E, et al. Immunology of alveolar and cystic echinococcosis (AE and CE). Adv Parasitol, 2017, 96: 1-54.
112.	Zhang Y, Li M, Du G, et al. Advancedoral vaccine delivery strategies for improving the immunity. Adv Drug Deliv Rev, 2021, 177: 113928. doi: 10.1016/j.addr.2021.113928.
113.	Davitt CJ, Lavelle EC. Delivery strategies to enhance oral vaccination against enteric infections. Adv Drug Deliv Rev, 2015, 91: 52-69.
114.	Heath DD, Koolaard J. Serological monitoring of protection of sheep against Echinococcus granulosus induced by the EG95 vaccine. Parasite Immunol, 2012, 34(1): 40-44.
115.	Dempster RP, Berridge MV, Harrison GB, et al. Echinococcus granulosus: development of an intermediate host mouse model for use in vaccination studies. Int J Parasitol, 1991, 21(5): 549-554.
116.	由弘, 張文寶, 甫拉提, 等. 細粒棘球絳蟲原發性感染動物模型的建立. 中國獸醫寄生蟲病, 2003, 11(2): 9-12.
117.	Streicker DG, Griffiths ME, Antia R, et al. Developing transmissible vaccines for animal infections. Science, 2024, 384(6693): 275-277.
118.	Torres JM, Sánchez C, Ramírez MA, et al. First field trial of a transmissible recombinant vaccine against myxomatosis and rabbit hemorrhagic disease. Vaccine, 2001, 19(31): 4536-4543.
119.	Casulli A, Abela-Ridder B, Petrone D, et al. Unveiling the incidences and trends of the neglected zoonosis cystic echinococcosis in Europe: a systematic review from the MEmE project. Lancet Infect Dis, 2023, 23(3): e95-e107. doi: 10.1016/S1473-3099(22)00638-7.
120.	Budke CM, Deplazes P, Torgerson PR. Global socioeconomic impact of cystic echinococcosis. Emerg Infect Dis, 2006, 12(2): 296-303.

1. McManus DP, Zhang W, Li J, et al. Echinococcosis. Lancet, 2003, 362(9392): 1295-1304.
2. 溫浩, 徐明謙. 實用包蟲病學. 北京: 科學出版社, 2007.
3. Eckert J, Deplazes P. Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. Clin Microbiol Rev, 2004, 17(1): 107-135.
4. Mandal S, Mandal MD. Human cystic echinococcosis: epidemiologic, zoonotic, clinical, diagnostic and therapeutic aspects. Asian Pac J Trop Med, 2012, 5(4): 253-260.
5. 中國醫師協會外科醫師分會包蟲病外科專業委員會. 肝兩型包蟲病診斷與治療專家共識(2019版). 中華消化外科雜志, 2019, 18(8): 711-721.
6. 唐桂波, 張強, 郭亞民, 等. 臨床包蟲病學. 北京: 人民衛生出版社, 2022.
7. WHO. Echinococcosis. 2021. https://www.who.int/en/news-room/fact-sheets/detail/echinococcosis.
8. World Health Organization?. Fact sheet on echinococcosis (?updated May 2019)?. Weekly Epidemiological Record, 2019, 94(?48): ?574-579.
9. 伍衛平, 王虎, 王謙, 等. 2012–2016年中國棘球蚴病抽樣調查分析. 中國寄生蟲學與寄生蟲病雜志, 2018, 36(1): 1-14.
10. 喻文杰, 王謙, 廖沙, 等. 2017年四川省石渠縣包蟲病患病情況現狀調查. 預防醫學情報雜志, 2018, 34(5): 545-549.
11. 王健, 王文濤. 肝包蟲病診療進展. 中華肝臟外科手術學電子雜志, 2022, 11(4): 351-355.
12. Joliat GR, Labgaa I, Demartines N, et al. Preoperative albumin level is a marker of alveolar echinococcosis recurrence after hepatectomy. World J Gastroenterol, 2017, 23(5): 853-858.
13. Wen H, Vuitton L, Tuxun T, et al. Echinococcosis: advances in the 21st century. Clin Microbiol Rev, 2019, 32(2): e00075-18. doi: 10.1128/CMR.00075-18.
14. 王志鑫, 劉云飛, 王灝, 等. 肝泡型包蟲病的診治進展. 器官移植, 2024, 15(2): 171-177.
15. 楊柳瑩, 陳曦陽, 凌攀, 等. 包蟲病特異性抗體檢測試劑盒診斷效能評價及結果判定優化. 寄生蟲與醫學昆蟲學報, 2021, 28(3): 143-147.
16. 劉文亞, 蔣奕, 王健. 肝包蟲病影像學診斷專家共識. 臨床肝膽病雜志, 2021, 37(4): 792-797.
17. Brunetti E, Kern P, Vuitton DA, et al. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop, 2010, 114(1): 1-16.
18. WHO. Working to overcome the global impact of neglected tropical diseases: first WHO report on neglected tropical diseases: summary. Geneva: World Health Organization, 2010.
19. WHO. Global report on neglected tropical diseases 2024. Geneva: World Health Organization, 2024.
20. Rong X, Fan M, Zhu H, et al. Dynamic modeling and optimal control of cystic echinococcosis. Infect Dis Poverty, 2021, 10(1): 38. doi: 10.1186/s40249-021-00807-6.
21. Nabarro LE, Amin Z, Chiodini PL. Current management of cystic echinococcosis: a survey of specialist practice. Clin Infect Dis, 2015, 60(5): 721-728.
22. Gu H, Hu Y, Guo S, et al. China’s prevention and control experience of echinococcosis: A 19-year retrospective. J Helminthol, 2024, 98: e16. doi: 10.1017/S0022149X24000014.
23. 健康中國2030規劃綱要. 中華眼科雜志, 2018, 54(1): 11-22.
24. Nandi A, Shet A. Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination. Hum Vaccin Immunother, 2020, 16(8): 1900-1904.
25. Lightowlers MW, Lawrence SB, Gauci CG, et al. Vaccination against hydatidosis using a defined recombinant antigen. Parasite Immunol, 1996, 18(9): 457-462.
26. Larrieu E, Gavidia CM, Lightowlers MW. Control of cystic echinococcosis: Background and prospects. Zoonoses Public Health, 2019, 66(8): 889-899.
27. Reuben JM, Tanner CE, Rau ME. Immunoprophylaxis with BCG of experimental Echinococcus multilocularis infections. Infect Immun, 1978, 21(1): 135-139.
28. Ritz N, Hanekom WA, Robins-Browne R, et al. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev, 2008, 32(5): 821-841.
29. Lange C, Aaby P, Behr MA, et al. 100 years of Mycobacterium bovis bacille Calmette-Guérin. Lancet Infect Dis, 2022, 22(1): e2-e12. doi: 10.1016/S1473-3099(21)00403-5.
30. Hataminejad M, Anvari D, Khaleghi N, et al. Current status and future prospects of Echinococcus multilocularis vaccine candidates: A systematic review. Vet Anim Sci, 2024, 24: 100345. doi: 10.1016/j.vas.2024.100345.
31. Rrudneva VG, Berezhko K, Sasikova R. Immunoprophylaxis of secondary alveolar echinococcosis by a immunostimulation ribotan combined with antigen protoscolex cells of Echinococcus multilocularis. Interdisciplinary Scientific Conference for PhD students and assistants, 2016.
32. Kouguchi H, Matsumoto J, Nakao R, et al. Characterization of a surface glycoprotein from Echinococcus multilocularis and its mucosal vaccine potential in dogs. PLoS One, 2013, 8(7): e69821. doi: 10.1371/journal.pone.0069821.
33. Hashemitabar GR, Razmi GR, Naghibi A. Trials to induce protective immunity in mice and sheep by application of protoscolex and hydatid fluid antigen or whole body antigen of Echinococcus granulosus. J Vet Med B Infect Dis Vet Public Health, 2005, 52(5): 243-245.
34. Hassan H, Al Hadithi TS, Al Sakee HM. Experimental trial with a heat-shocked protoscolex extract as a vaccine candidate for protection against hydatid disease. Turkiye Parazitol Derg, 2016, 40(1): 1-8.
35. Zhang W, Zhang Z, Shi B, et al. Vaccination of dogs against Echinococcus granulosus, the cause of cystic hydatid disease in humans. J Infect Dis, 2006, 194(7): 966-974.
36. Kandil OM, Abdelrahman KA, Mahmoud MS, et al. Cystic echinococcosis: Development of an intermediate host rabbit model for using in vaccination studies. Exp Parasitol, 2020, 208: 107800. doi: 10.1016/j.exppara.2019.107800.
37. El-Aal AA, El-Gebaly NS, Al-Antably AS, et al. Post-immunization immunohistochemical expression of Caspase 3 and p53 apoptotic markers in experimental hydatidosis. Rev Bras Parasitol Vet, 2016, 25(3): 333-340.
38. Poggio TV, Jensen O, Mossello M, et al. Serology and longevity of immunity against Echinococcus granulosus in sheep and llama induced by an oil-based EG95 vaccine. Parasite Immunol, 2016, 38(8): 496-502.
39. Gottstein B, Wunderlin E, Tanner I. Echinococcus multilocularis: parasite-specific humoral and cellular immune response subsets in mouse strains susceptible (AKR, C57B1/6J) or ‘resistant’ (C57B1/10) to secondary alveolar echinococcosis. Clin Exp Immunol, 1994, 96(2): 245-252.
40. Jazouli M, Lightowlers MW, Bamouh Z, et al. Immunological responses and potency of the EG95NC^– recombinant sheep vaccine against cystic echinococcosis. Parasitol Int, 2020, 78: 102149. doi: 10.1016/j.parint.2020.102149.
41. Barnes TS, Hinds LA, Jenkins DJ, et al. Efficacy of the EG95 hydatid vaccine in a macropodid host, the tammar wallaby. Parasitology, 2009, 136(4): 461-468.
42. Heath DD, Robinson C, Lightowlers MW. Maternal antibody parameters of cattle and calves receiving EG95 vaccine to protect against Echinococcus granulosus. Vaccine, 2012, 30(50): 7321-7326.
43. Larrieu E, Herrero E, Mujica G, et al. Pilot field trial of the EG95 vaccine against ovine cystic echinococcosis in Rio Negro, Argentina: early impact and preliminary data. Acta Trop, 2013, 127(2): 143-151.
44. Amarir F, Rhalem A, Sadak A, et al. Control of cystic echinococcosis in the Middle Atlas, Morocco: Field evaluation of the EG95 vaccine in sheep and cesticide treatment in dogs. PLoS Negl Trop Dis, 2021, 15(3): e0009253. doi: 10.1371/journal.pntd.0009253.
45. Gauci CG, Jenkins DJ, Lightowlers MW. Protection against cystic echinococcosis in sheep using an Escherichia coli-expressed recombinant antigen (EG95) as a bacterin. Parasitology, 2022, 150(1): 1-3.
46. Lightowlers MW, Jensen O, Fernandez E, et al. Vaccination trials in Australia and Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep. Int J Parasitol, 1999, 29(4): 531-534.
47. Gauci C, Lightowlers MW. Molecular cloning of genes encoding oncosphere proteins reveals conservation of modular protein structure in cestode antigens. Mol Biochem Parasitol, 2003, 127(2): 193-198.
48. 張壯志, 石保新, 張文寶, 等. 綿羊包蟲病基因工程疫苗(Eg95)免疫試驗. 中國人獸共患病學報, 2008, 24(3): 252-256.
49. Woollard DJ, Gauci CG, Heath DD, et al. Protection against hydatid disease induced with the EG95 vaccine is associated with conformational epitopes. Vaccine, 2000, 19(4-5): 498-507.
50. 張藝琳. EG95誘導的抗體應答在細粒棘球蚴感染中的保護機制. 成都: 四川大學, 2021.
51. Jazouli M, Lightowlers M, Gauci CG, et al. Vaccination against hydatidosis: Molecular cloning and optimal expression of the EG95NC^– recombinant antigen in Escherichia coli. Protein J, 2017, 36(6): 472-477.
52. Pourseif MM, Moghaddam G, Nematollahi A, et al. Vaccination with rEGVac elicits immunoprotection against different stages of Echinococcus granulosus life cycle: A pilot study. Acta Trop, 2021, 218: 105883. doi: 10.1016/j.actatropica.2021.105883.
53. Zhang ZZ, Guo G, Li J, et al. Dog vaccination with EgM proteins against Echinococcus granulosus. Infect Dis Poverty, 2018, 7(1): 61. doi: 10.1186/s40249-018-0425-4.
54. Shi Z, Wang Y, Li Z, et al. Cloning, expression, and protective immunity in mice of a gene encoding the diagnostic antigen P-29 of Echinococcus granulosus. Acta Biochim Biophys Sin (Shanghai), 2009, 41(1): 79-85.
55. Li ZJ, Wang YN, Wang Q, et al. Echinococcus granulosus 14-3-3 protein: a potential vaccine candidate against challenge with Echinococcus granulosus in mice. Biomed Environ Sci, 2012, 25(3): 352-358.
56. Li Z, Ding S, Li Y. Study on the immunity protection of 14-3-3-MPLA-liposome vaccine against cystic echinococcosis in mice. Front Lab Med, 2018, 2(4): 146-151.
57. Arbildi P, Muniz-Lagos AC, Fernández E, et al. Immunization with a Mu-class glutathione transferase from Echinococcus granulosus induces efficient antibody responses and confers long-term protection against secondary cystic echinococcosis. Microbes Infect, 2024, 26(5-6): 105364. doi: 10.1016/j.micinf.2024.105364.
58. Siles-Lucas M, Merli M, Mackenstedt U, et al. The Echinococcus multilocularis 14-3-3 protein protects mice against primary but not secondary alveolar echinococcosis. Vaccine, 2003, 21(5-6): 431-439.
59. Dang Z, Yagi K, Oku Y, et al. Evaluation of Echinococcus multilocularis tetraspanins as vaccine candidates against primary alveolar echinococcosis. Vaccine, 2009, 27(52): 7339-7345.
60. Kouguchi H, Matsumoto J, Katoh Y, et al. The vaccination potential of EMY162 antigen against Echinococcus multilocularis infection. Biochem Biophys Res Commun, 2007, 363(4): 915-920.
61. Gauci C, Merli M, Muller V, et al. Molecular cloning of a vaccine antigen against infection with the larval stage of Echinococcus multilocularis. Infect Immun, 2002, 70(7): 3969-3972.
62. Chen L, Cheng Z, Xian S, et al. Immunization with Em CRT-induced protective immunity against Echinococcus multilocularis infection in BALB/c mice. Trop Med Infect Dis, 2022, 7(10): 279. doi: 10.3390/tropicalmed7100279.
63. Wang H, Li Z, Gao F, et al. Immunoprotection of recombinant Eg. P29 against Echinococcus granulosus in sheep. Vet Res Commun, 2016, 40(2): 73-79.
64. Müller-Schollenberger V, Beyer W, Schnitzler P, et al. Immunisation with Salmonella typhimurium-delivered glyceraldehyde-3-phosphate dehydrogenase protects mice against challenge infection with Echinococcus multilocularis eggs. Int J Parasitol, 2001, 31(13): 1441-1449.
65. Wang Y, Li Z, Li Z, et al. Recombinant ferritin protects mice against challenge with Echinococcus granulosus ?. Acta Parasitologica, 2009, 54(4): 335-340.
66. Sun J, Wang Y, Li Z, et al. Echinococcus granulosus: immunoprotection accompanyied by humoral and cytokine response against secondary hydatidosis in mice immunized with rEg. myophilin. Vet Res Commun, 2011, 35(4): 193-200.
67. Zhu M, Gao F, Li Z, et al. Immunoprotection of recombinant Eg. myophilin against Echinococcus granulosus infection in sheep. Exp Ther Med, 2016, 12(3): 1585-1590.
68. Li R, Yang Q, Guo L, et al. Immunological features and efficacy of the recombinant subunit vaccine LTB-EMY162 against Echinococcus multilocularis metacestode. Appl Microbiol Biotechnol, 2018, 102(5): 2143-2154.
69. Zhu M, Wang X, Wang H, et al. Mechanism of protective immunity by vaccination with recombinant Echinococcus granulosus glutathione S-transferase (Chinese strain) in mice. Exp Ther Med, 2015, 10(3): 1127-1132.
70. Wang L, Wei W, Zhou P, et al. Enzymatic characteristics and preventive effect of leucine aminopeptidase against Echinococcus multilocularis. Acta Trop, 2021, 222: 106066. doi: 10.1016/j.actatropica.2021.106066.
71. Boubaker G, Hemphill A, Huber CO, et al. Prevention and immunotherapy of secondary murine alveolar echinococcosis employing recombinant EmP29 antigen. PLoS Negl Trop Dis, 2015, 9(6): e0003795. doi: 10.1371/journal.pntd.0003795.
72. Li M, Zhu Y, Li Z, et al. Immunoprotective effect and mechanism of rEg. P29 against CD4⁺ T cell-deficient mice with Echinococcus multilocularis infection. Acta Biochim Biophys Sin (Shanghai), 2024, 56(3): 482-489.
73. Dang Z, Yagi K, Oku Y, et al. A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology. PLoS Negl Trop Dis, 2012, 6(3): e1570. doi: 10.1371/journal.pntd.0001570.
74. Xian J, Wang N, Zhao P, et al. Molecular characterization and immune protection of the 3-hydroxyacyl-CoA dehydrogenase gene in Echinococcus granulosus. Parasit Vectors, 2021, 14(1): 489. doi: 10.1186/s13071-021-05001-z.
75. Shao G, Hua R, Song H, et al. Protective efficacy of six recombinant proteins as vaccine candidates against Echinococcus granulosus in dogs. PLoS Negl Trop Dis, 2023, 17(10): e0011709. doi: 10.1371/journal.pntd.0011709.
76. Xian J, Zhao P, Wang N, et al. Molecular characterization of a tetraspanin TSP11 gene in Echinococcus granulosus and evaluation its immunoprotection in model dogs. Front Vet Sci, 2021, 8: 759283. doi: 10.3389/fvets.2021.759283.
77. Virginio VG, Monteiro KM, Drumond F, et al. Excretory/secretory products from in vitro-cultured Echinococcus granulosus protoscoleces. Mol Biochem Parasitol, 2012, 183(1): 15-22.
78. Esteves A, Portillo V, Ehrlich R. Genomic structure and expression of a gene coding for a new fatty acid binding protein from Echinococcus granulosus. Biochim Biophys Acta, 2003, 1631(1): 26-34.
79. Fraize M, Sarciron ME, Azzouz S, et al. Immunogenicity of two Echinococcus granulosus antigens EgA31 and EgTrp in mice. Parasitol Res, 2005, 96(2): 113-120.
80. 吳茂迪. 細粒棘球絳蟲PGK、E2D2基因的特征分析及EgFABP-EgA31、EgTPx-EgTrp蛋白免疫保護效果評價. 成都: 四川農業大學, 2019.
81. 葉艷菊. 細粒棘球絳蟲轉Eg95-EgA31融合基因苜蓿疫苗保護力及其免疫機制研究. 重慶: 重慶醫科大學, 2010.
82. Williams JA, Carnes AE, Hodgson CP. Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production. Biotechnol Adv, 2009, 27(4): 353-370.
83. Zhao Y, Bi Q, Wei Y, et al. A DNA vaccine (EG95-PT1/2/3-IL2) encoding multi-epitope antigen and IL-2 provokes efficient and long-term immunity to echinococcosis. J Control Release, 2023, 361: 402-416.
84. Boutennoune H, Qaqish A, Al-Aghbar M, et al. Induction of T helper 1 response by immunization of BALB/c mice with the gene encoding the second subunit of Echinococcus granulosus antigen B (EgAgB8/2). Parasite, 2012, 19(2): 183-188.
85. Gharibi Z, Rahdar M, Pirestani M, et al. The immunization of protoscolices P29 DNA vaccine on experimental cystic echinococosis in Balb/c mice. Acta Parasitol, 2021, 66(4): 1114-1121.
86. Azizi H, Kazemi B, BandehpouR M, et al. Modulation of the immune response to DNA vaccine encoding gene of 8-kDa subunit of Echinococcus granulosus antigen B using murine interleukin-12 plasmid in BALB/c mice. Iran J Parasitol, 2016, 11(4): 480-489.
87. Anvari D, Rezaei F, Ashouri A, et al. Current situation and future prospects of Echinococcus granulosus vaccine candidates: A systematic review. Transbound Emerg Dis, 2021, 68(3): 1080-1096.
88. Pourseif MM, Moghaddam G, Saeedi N, et al. Current status and future prospective of vaccine development against Echinococcus granulosus. Biologicals, 2018, 51: 1-11.
89. Pagliari S, Dema B, Sanchez-Martinez A, et al. DNA vaccines: History, molecular mechanisms and future perspectives. J Mol Biol, 2023, 435(23): 168297. doi: 10.1016/j.jmb.2023.168297.
90. 楊先偉, 陶浪, 魏金文, 等. 包蟲病特異性疫苗抗原研究現狀及展望. 中國普外基礎與臨床雜志, 2023, 30(6): 734-738.
91. Esmaelizad M, Ahmadian G, Aghaiypour K, et al. Induction of prominent Th1 response in C57Bl/6 mice immunized with an E. coli-expressed multi T-cell epitope EgA31 antigen against Echinococcus granulosus. Folia Parasitol (Praha), 2013, 60(1): 28-34.
92. Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov, 2018, 17(4): 261-279.
93. Gote V, Bolla PK, Kommineni N, et al. A comprehensive review of mRNA vaccines. Int J Mol Sci, 2023, 24(3): 2700. doi: 10.3390/ijms24032700.
94. Schlake T, Thess A, Fotin-Mleczek M, et al. Developing mRNA-vaccine technologies. RNA Biol, 2012, 9(11): 1319-1330.
95. Xu S, Yang K, Li R, et al. mRNA vaccine Era-mechanisms, drug platform and clinical prospection. Int J Mol Sci, 2020, 21(18): 6582. doi: 10.3390/ijms21186582.
96. Yu M, Zhu Y, Li Y, et al. Design of a novel multi-epitope vaccine against Echinococcus granulosus in immunoinformatics. Front Immunol, 2021, 12: 668492. doi: 10.3389/fimmu.2021.668492.
97. Lv Y, Zhu Y, Chang L, et al. Identification of a dominant murine T-cell epitope in recombinant protein P29 from Echinococcus granulosus. Acta Biochim Biophys Sin (Shanghai), 2022, 54(4): 482-493.
98. Zhao X, Zhang F, Li Z, et al. Bioinformatics analysis of EgA31 and EgG1Y162 proteins for designing a multi-epitope vaccine against Echinococcus granulosus. Infect Genet Evol, 2019, 73: 98-108.
99. Li Y, Zhu Y, Sha T, et al. A multi-epitope chitosan nanoparticles vaccine of canine against Echinococcus granulosus. J Biomed Nanotechnol, 2021, 17(5): 910-920.
100. An X, Xiang W, Liu X, et al. A bioengineered nanovesicle vaccine boosts T-B cell interaction for immunotherapy of Echinococcus multilocularis. Angew Chem Int Ed Engl, 2024, 63(13): e202319489. doi: 10.1002/anie.202319489.
101. Petavy AF, Hormaeche C, Lahmar S, et al. An oral recombinant vaccine in dogs against Echinococcus granulosus, the causative agent of human hydatid disease: a pilot study. PLoS Negl Trop Dis, 2008, 2(1): e125. doi: 10.1371/journal.pntd.0000125.
102. Chabalgoity JA, Moreno M, Carol H, et al. Salmonella typhimurium as a basis for a live oral Echinococcus granulosus vaccine. Vaccine, 2000, 19(4-5): 460-469.
103. 李文桂, 王鴻, 朱佑明. 細粒棘球絳蟲重組BCG-Eg95疫苗誘導小鼠脾細胞淋巴因子變化的研究. 中國寄生蟲學與寄生蟲病雜志, 2007, 25(2): 109-113.
104. Ebrahimzadeh F, Shirdast H, Taromchi A, et al. Induction of immunogenic response in BALB/c mice by live and killed form of recombinant lactococcus lactis displaying EG95 of Echinococcus granulosus. Iran Biomed J, 2021, 25(4): 284-296.
105. 周必英, 李文桂. 細粒棘球絳蟲重組Bb-Eg95疫苗誘導小鼠體液免疫應答的動態觀察. 中國病原生物學雜志, 2012, 7(7): 513-515.
106. Xu T, Liu L, Shi C, et al. A recombinant rabies virus expressing Echinococcus granulosus EG95 induces protective immunity in mice. Transbound Emerg Dis, 2022, 69(4): e254-e266. doi: 10.1111/tbed.14292.
107. Ma X, Zhao H, Zhang F, et al. Activity in mice of recombinant BCG-EgG1Y162 vaccine for Echinococcus granulosus infection. Hum Vaccin Immunother, 2016, 12(1): 170-175.
108. 周必英, 陳雅棠, 李文桂, 等. 細粒棘球絳蟲重組Bb-Eg95-EgA31疫苗誘導小鼠脾細胞因子變化的研究. 中國寄生蟲學與寄生蟲病雜志, 2010, 28(4): 268-272.
109. 李文桂, 王鴻, 朱佑明. 多房棘球絳蟲混合重組BCG-EmⅡ/3和BCG-Em14-3-3疫苗誘導小鼠的免疫保護力觀察. 第三軍醫大學學報, 2007, 29(13): 1276-1279.
110. 楊梅, 李文桂. 多房棘球絳蟲重組Bb-EmⅡ/3-Em14-3-3疫苗誘導小鼠細胞因子變化的研究. 細胞與分子免疫學雜志, 2008, 24(8): 781-784.
111. Gottstein B, Soboslay P, Ortona E, et al. Immunology of alveolar and cystic echinococcosis (AE and CE). Adv Parasitol, 2017, 96: 1-54.
112. Zhang Y, Li M, Du G, et al. Advancedoral vaccine delivery strategies for improving the immunity. Adv Drug Deliv Rev, 2021, 177: 113928. doi: 10.1016/j.addr.2021.113928.
113. Davitt CJ, Lavelle EC. Delivery strategies to enhance oral vaccination against enteric infections. Adv Drug Deliv Rev, 2015, 91: 52-69.
114. Heath DD, Koolaard J. Serological monitoring of protection of sheep against Echinococcus granulosus induced by the EG95 vaccine. Parasite Immunol, 2012, 34(1): 40-44.
115. Dempster RP, Berridge MV, Harrison GB, et al. Echinococcus granulosus: development of an intermediate host mouse model for use in vaccination studies. Int J Parasitol, 1991, 21(5): 549-554.
116. 由弘, 張文寶, 甫拉提, 等. 細粒棘球絳蟲原發性感染動物模型的建立. 中國獸醫寄生蟲病, 2003, 11(2): 9-12.
117. Streicker DG, Griffiths ME, Antia R, et al. Developing transmissible vaccines for animal infections. Science, 2024, 384(6693): 275-277.
118. Torres JM, Sánchez C, Ramírez MA, et al. First field trial of a transmissible recombinant vaccine against myxomatosis and rabbit hemorrhagic disease. Vaccine, 2001, 19(31): 4536-4543.
119. Casulli A, Abela-Ridder B, Petrone D, et al. Unveiling the incidences and trends of the neglected zoonosis cystic echinococcosis in Europe: a systematic review from the MEmE project. Lancet Infect Dis, 2023, 23(3): e95-e107. doi: 10.1016/S1473-3099(22)00638-7.
120. Budke CM, Deplazes P, Torgerson PR. Global socioeconomic impact of cystic echinococcosis. Emerg Infect Dis, 2006, 12(2): 296-303.

Previous Article
Hepatic echinococcosis: Novel detection methods
Next Article
Anesthesia management in hepatic echinococcosis surgery

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Advances in research and development of echinococcosis vaccines

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content